title: [Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting].
abstract: The prevalence of HCV infection in Spanish prisons is very high (38.5%). The characteristics of the infected patients, particularly the high rate of HIV coinfection, makes it very likely that the morbidity and mortality produced by serious liver disease secondary to this infection will increase considerably in the coming years. A group of Spanish experts with experience in patients who are inmates has been invited to establish a series of recommendations for the diagnosis and treatment of chronic hepatitis C infection in Spanish prisons.
authors.affiliation: Servicios Médicos, Centro Penitenciario Alicante I, Alicante, España. pabloshz@coma.es
authors.forename: Pablo
authors.initials: P
authors.lastname: Saiz de la Hoya-Zamácola
authors.forename: Andrés
authors.initials: A
authors.lastname: Marco-Mouriño
authors.forename: Gerardo
authors.initials: G
authors.lastname: Clemente-Ricote
authors.forename: Joaquín
authors.initials: J
authors.lastname: Portilla-Sogorb
authors.forename: Vicente
authors.initials: V
authors.lastname: Boix-Martínez
authors.forename: Oscar
authors.initials: O
authors.lastname: Núñez-Martínez
authors.forename: Sergio
authors.initials: S
authors.lastname: Reus-Bañuls
authors.forename: Nuria
authors.initials: N
authors.lastname: Teixidó i Pérez
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D015897:Comorbidity; D018450:Disease Progression; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008099:Liver / Q000473:pathology / Q000821:virology; D008111:Liver Function Tests; D010349:Patient Compliance; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011329:Prisoners / Q000706:statistics & numerical data; D011330:Prisons; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology; D015819:Substance Abuse, Intravenous / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a